Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025
Plus Therapeutics announced that Phase 1 single-dose escalation results from its ReSPECT-LM trial in leptomeningeal metastases will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) as a poster spotlight with an oral component. 45
The accepted abstract focuses on REYOBIQ, a targeted radiotherapeutic administered into the cerebrospinal fluid for patients with leptomeningeal metastases, a serious complication of advanced cancers including breast cancer. 25
Earlier ReSPECT-LM Phase 1 single-dose escalation data have shown that treatment with REYOBIQ was feasible, had a manageable safety profile, and produced early signs of clinical benefit in patients with leptomeningeal metastases. 12
At a prior 2025 SNO/ASCO CNS metastases meeting, ReSPECT-LM Phase 1 data reported a clinical benefit rate above 75% across multiple outcome measures, with no dose-limiting toxicities up to the recommended Phase 2 dose of 44.1 mCi. 1
REYOBIQ in the ReSPECT-LM program has received FDA Fast Track and Orphan Drug designations for leptomeningeal metastases, supporting expedited development for this high‑unmet‑need indication. 15
Plus Therapeutics has indicated that enrollment and further evaluation continue in follow‑on ReSPECT-LM studies, including dose optimization, to confirm and expand on the Phase 1 findings. 15
Sources:
1. https://www.stocktitan.net/news/PSTV/plus-therapeutics-highlights-re-spect-lm-clinical-trial-results-at-ti6ro53817w2.html
2. https://www.respect-trials.com/post-positive-respect-lm-phase-1-data-at-sno-asco-cns-metastases-conference/
4. https://www.chartmill.com/news/PSTV/globenews-2025-12-1-plus-therapeutics-to-present-respect-phase-1-dose-escalation-study-results-for-leptomeningeal-metastases-at-the-2025-san-antonio-breast-cancer-symposium